CAR-transduced NK cell therapy

Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children's National Health System, Washington, DC, discusses the potential role of chimeric antigen receptor (CAR)-transduced natural killer (NK) cells. Prof. Bollard reports that a recent study demonstrated the safe use of CD19 CAR-NK cells in B-cell malignancies. In addition, these cells are associated with IL-15, which enhances the survival of these cells. Larger studies are required to test the efficacy of these CAR-NK products in the clinic. Prof. Bollard also comments on the growing interest in CAR-transduced NK cells for solid tumors. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.